Renovaro Biosciences · ISIN: US29350E1047

Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 8, 2025 / Renovaro Inc. (NASDAQ:RENB) was referenced in a recent RealClearDefense article titled "AI Can Be Used to Develop Biological and Chemical Weapons", which examines the complex challenges posed by artificial intelligence in the context of global security and biodefense.The full ar...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 08.08.2025 | 10:45
08 August 2025 10:45AM
Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks
LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 8, 2025 / Renovaro Inc. (NASDAQ:RENB) was referenced in a recent RealClearDefense article titled "AI Can Be Used to Develop Biological and Chemical Weapons", which examines the complex challenges posed by artificial intelligence in the context of global security and biodefense.The full ar...
Renovaro Biosciences
© ACCESSWIRE
28 July 2025 10:38AM
Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector
Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 28, 2025 / Renovaro (NASDAQ:RENB), a precision-medicine technology company, today announced multiple U.S. patent allowances that significantly strengthen i...
Renovaro Biosciences
© ACCESSWIRE
17 July 2025 09:15AM
Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy
Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro Biosciences (NASDAQ:RENB), an oncology and neurology focused TechBio company, today announced the publication of a peer-reviewed study in Vaccines, a...
Renovaro Biosciences
© ACCESSWIRE
09 July 2025 08:00AM
Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives
LOS ANGELES, CA / ACCESS Newswire / July 9, 2025 / Renovaro Inc. (NASDAQ:RENB), an AI-driven precision medicine company, today announced that senior debt holders have agreed to convert an aggregate of approximately $9.7 million of outstanding senior debt into convertible debt which they have elected to convert into equity.Under the terms of the ag...
Renovaro Biosciences
© ACCESSWIRE
30 June 2025 09:21AM
Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs
LOS ANGELES, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents, including weaponized substances like Sarin. The platform has been integra...
Renovaro Biosciences
© ACCESSWIRE
10 June 2025 05:17PM
Smart Healthcare Is Taking Over. Here's Where the Money's Headed
Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /PRNewswire/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speec...
Renovaro Biosciences
© PR Newswire
10 June 2025 05:13PM
Smart Healthcare Is Taking Over. Here's Where the Money's Headed
Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /PRNewswire/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speec...
Renovaro Biosciences
© PR Newswire
10 June 2025 05:13PM
Smart Healthcare Is Taking Over. Here's Where the Money's Headed
Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /CNW/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches fro...
Renovaro Biosciences
© PR Newswire
03 June 2025 01:15PM
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform...
Renovaro Biosciences
© Globe Newswire
22 May 2025 07:12PM
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology...
Renovaro Biosciences
© Globe Newswire
22 May 2025 03:05PM
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology...
Renovaro Biosciences
© Globe Newswire
14 May 2025 01:15PM
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform...
Renovaro Biosciences
© Globe Newswire
13 May 2025 01:15PM
Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics
Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics...
Renovaro Biosciences
© Globe Newswire
22 April 2025 01:20PM
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs...
Renovaro Biosciences
© Globe Newswire
09 April 2025 01:25PM
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine...
Renovaro Biosciences
© Globe Newswire
04 April 2025 01:40PM
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
Renovaro Provides Update to Definitive Agreement with Predictive Oncology...
Renovaro Biosciences
© Globe Newswire
03 March 2025 02:15PM
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology...
Renovaro Biosciences
© Globe Newswire
26 February 2025 06:25PM
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine...
Renovaro Biosciences
© Globe Newswire
26 February 2025 02:15PM
Renovaro Announces $15 million in Equity Committed
Renovaro Announces $15 million in Equity Committed...
Renovaro Biosciences
© Globe Newswire
07 January 2025 02:15PM
Renovaro Appoints Nathen Fuentes as Chief Financial Officer
Renovaro Appoints Nathen Fuentes as Chief Financial Officer...
Renovaro Biosciences
© Globe Newswire
07 January 2025 02:15PM
Renovaro Issues Shareholder Letter and Provides Corporate Update
Renovaro Issues Shareholder Letter and Provides Corporate Update...
Renovaro Biosciences
© Globe Newswire
06 January 2025 02:15PM
Renovaro to Acquire Predictive Oncology in All-Stock Transaction
Renovaro to Acquire Predictive Oncology in All-Stock Transaction...
Renovaro Biosciences
© Globe Newswire
30 December 2024 02:00PM
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV...
Renovaro Biosciences
© Globe Newswire
20 December 2024 08:40PM
Renovaro Regains Compliance with NASDAQ Listing Requirement
Renovaro Regains Compliance with NASDAQ Listing Requirement...
Renovaro Biosciences
© Globe Newswire
17 October 2024 01:15PM
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024....
Renovaro Biosciences
© Globe Newswire
16 October 2024 01:28PM
Renovaro Announces Strategic Restructuring and Leadership Transition
LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company’s AI Platform, RenovaroCub...
Renovaro Biosciences
© Globe Newswire
13 September 2024 01:00PM
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024....
Renovaro Biosciences
© Globe Newswire
11 September 2024 01:15PM
RenovaroCube Announces Strategic Offering of Up to 20% Ownership
AMSTERDAM, Sept. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) The Board of Renovaro, Inc (RENB) intends to seek strategic investors to acquire up to 20% of RenovaroCube (Cube), currently a wholly owned subsidiary....
Renovaro Biosciences
© Globe Newswire
14 June 2024 01:06PM
Renovaro, Inc. Announces $10 million in Equity Committed
Renovaro Announces $10m in Equity Committed...
Renovaro Biosciences
© Globe Newswire
24 May 2024 01:20PM
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy...
Renovaro Biosciences
© Globe Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.